Aug 29, 2019

Starpharma sees positive results in ovarian cancer treatment

Starpharma sees positive results in ovarian cancer treatment

Online investor news outlet Finance News Network reported  Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model.

To watch the full news video, click here.

 This contains certain forward-looking statements.